Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5’-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.